Novartis stock price: NOVN ends higher on FDA Breakthrough tag for Sjögren’s drug ianalumab

Zurich, January 18, 2026, 20:45 CET — The market has closed.

Novartis shares rose close to 1% on Friday after the Swiss pharma giant announced that U.S. regulators had granted a Breakthrough Therapy designation to ianalumab, its drug candidate for Sjögren’s disease. The stock finished at 115.60 Swiss francs on the SIX Swiss Exchange. (MarketWatch)

The designation is important because it aims to accelerate development and review for drugs targeting serious illnesses when early clinical data indicate they might outperform existing treatments. It also often leads to more frequent FDA engagement and a quicker route toward submitting an application — though it doesn’t equate to approval. (U.S. Food and Drug Administration)

Swiss trading kicks off again Monday, and investors will quickly find out if Friday’s move has legs in a market growing more selective about healthcare stocks. The Swiss Market Index dropped 0.47% on Friday, even as Europe’s healthcare sector ended higher. That leaves Novartis room to stand out on stock-specific news. (MarketWatch)

Novartis announced it will start global regulatory submissions for ianalumab early in 2026, positioning the drug as the first targeted treatment in an area with few options. “This designation recognises the potential for ianalumab to improve care for people with Sjögren’s disease, who lack effective options,” said Angelika Jahreis, global head of development for immunology at Novartis. (Novartis)

U.S. investors will get their next trading opportunity a day later than normal. Markets are shut Monday in observance of Martin Luther King Jr. Day, Reuters reported. (Reuters)

Novartis’ U.S.-listed ADRs climbed to $144.34, marking a roughly 0.8% gain from the previous close, per market data.

Broker sentiment stayed divided. UBS analyst Matthew Weston held onto a Neutral rating but bumped up his target price to 116 Swiss francs, according to a dpa-AFX note published on MarketScreener. (MarketScreener)

Breakthrough Therapy designation isn’t a guaranteed fast track to market. Timelines often slip, regulators may demand additional data, and late-stage trials can come up short — any of which can flip a Friday rally into a Monday selloff.

Novartis will report its fourth-quarter and full-year results on Feb. 4, also providing updates on guidance and pipeline milestones. (Novartis)

Khadija Saeed Latest posts

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

View all

Medtronic advances into 2026 on diabetes spin-off, Hugo system, and steady dividends
January 18, 2026, 4:43 PM EST. Medtronic (MDT) is trading on the prospect that a planned stand-alone spin-off of its diabetes business will sharpen focus on B2B operations and lift margins. Management has signaled the split should close by year-end 2026, reducing exposure to consumer diabetes care, which generated about 8% of revenue but only 4% of operating profit in fiscal 2025. A new growth driver comes from the Hugo robotic-assisted surgery (RAS) system, cleared in the U.S. for urologic procedures. While near-term top-line impact is modest, the device targets an underpenetrated market with long-term potential. Finally, Medtronic boasts a lengthy dividend streak, raising payouts for 48 consecutive years and offering about a 3% forward yield, with the potential to join the Dividend King club after 50 straight raises.